MHRA: Retifanlimab ZYNYZ Approved for Anal Cancer

• The MHRA has approved retifanlimab (ZYNYZ) for adults with advanced squamous cell carcinoma of the anal canal (SCAC).
• This approval, granted on November 11, 2026, to Incyte Biosciences UK Ltd., was processed via the International Recognition Procedure (IRP).
• Retifanlimab works by helping the immune system identify and attack cancer cells, and is administered intravenously every four weeks.
• For the first six cycles, the treatment is given in combination with carboplatin and paclitaxel chemotherapy.
• A study of 308 patients showed retifanlimab plus chemotherapy was more effective than placebo plus chemotherapy in increasing progression-free survival.

Pharmaceutical and healthcare lawyers in the UK should note this MHRA approval of Retifanlimab (ZYNYZ) as a new treatment option for advanced anal cancer, particularly its approval via the International Recognition Procedure (IRP), which sets a precedent for future drug market entry strategies.

The Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval for retifanlimab (ZYNYZ) to treat adults diagnosed with squamous cell carcinoma of the anal canal (SCAC). This new therapeutic option is specifically indicated for patients whose cancer cannot be surgically removed, has spread to other parts of the body, or has recurred in the same anatomical region as the original tumor.

This significant regulatory decision, issued on November 11, 2026, to Incyte Biosciences UK Ltd., introduces a new treatment pathway for a challenging form of cancer. Retifanlimab operates by bolstering the body's immune response, enabling it to better identify and combat cancer cells. It achieves this by obstructing a specific pathway that cancer cells exploit to evade detection by the immune system.

The drug is administered via an intravenous infusion, typically lasting about 30 minutes, on a four-week cycle. For the initial six treatment cycles, retifanlimab is prescribed in conjunction with carboplatin and paclitaxel, which are established chemotherapy agents. The MHRA emphasized that it will maintain close surveillance over the safety and efficacy of retifanlimab as its usage becomes more widespread across the UK.

The approval of retifanlimab (ZYNYZ) for advanced anal cancer was facilitated through the International Recognition Procedure (IRP), a regulatory pathway designed to streamline the market entry of medicines that have already received authorization from trusted international regulatory bodies. This mechanism allows the MHRA to leverage assessments from other stringent regulators, potentially accelerating access to new treatments within the UK.

As the primary regulatory body for medicines and medical devices in the United Kingdom, the MHRA is tasked with ensuring that all products are both effective and acceptably safe for public use. Their decisions are grounded in robust, evidence-based evaluations, ensuring that the potential benefits of any approved medicine outweigh its associated risks. This approval via the IRP underscores the MHRA's commitment to providing timely access to innovative therapies while upholding rigorous safety and efficacy standards.

Pharmaceutical and healthcare lawyers in the UK should note this MHRA approval of Retifanlimab (ZYNYZ) as a new treatment option for advanced anal cancer, particularly its approval via the International Recognition Procedure (IRP), which sets a precedent for future drug market entry strategies. Compliance officers in pharmaceutical companies should assess competitive landscape and regulatory obligations.

The efficacy of retifanlimab in treating SCAC was demonstrated in a clinical study involving 308 individuals with metastatic or locally advanced squamous cell carcinoma of the anal canal. The findings indicated that patients receiving retifanlimab in combination with chemotherapy experienced a longer period without their cancer worsening, compared to those who received a placebo alongside chemotherapy.

This recent approval for anal cancer is not the first for retifanlimab in the UK. The MHRA had previously approved the drug on July 6, 2026, for the treatment of adults with advanced Merkel cell carcinoma (MCC), a rare and aggressive form of skin cancer. This earlier authorization highlights the drug's potential across different cancer types where immune checkpoint inhibition can be beneficial. Further details regarding side effects and product characteristics are available in the Patient Information Leaflet and Summary of Product Characteristics on the MHRA website.

Source: Original reporting via MHRA press release